WorldCat Identities

Folkman, M. Judah

Overview
Works: 31 works in 60 publications in 3 languages and 2,053 library holdings
Genres: Abstracts  Biography 
Roles: Editor, Author
Classifications: QP106.6, 612.13
Publication Timeline
.
Most widely held works by M. Judah Folkman
Angiogenesis an integrative approach from science to medicine by William D Figg( )
15 editions published between 2007 and 2008 in English and held by 685 WorldCat member libraries worldwide
A comprehensive, concise summary of tumor angiogenesis. This book is a reference for the angiogenesis field as it relates to oncology
Cancer warrior ( Visual )
2 editions published in 2001 in English and held by 221 WorldCat member libraries worldwide
"'Cancer Warrior" is the story of an impassioned surgeon, Dr. Judah Folkman, and his struggle to pioneer a cancer treatment that for years went against the grain of many in the cancer research community. In 1960 when he was a surgical resident, Folkman was drafted by the U.S. Navy to help find a substitute for whole blood to meet the navy's needs for transfusable blood on long voyages. What he discovered instead was a startling secret about how cancer grows. It was a clue he would pursue for the next forty years. Dr. Judah Folkman, who has never been filmed for television before, has granted NOVA exclusive access to his much sought-after story. It is an incredible saga of personal dedication, of scientific blind alleys and breakthroughs, in a race to defeat one of humanity's most invincible foes. Judah Folkman shares his forty-year quest of a radically new cancer treatment including the development of the drug Endostatin. Discussed are anti-angiogenic drugs and how they can slow tumor growth by stopping the process of developing new blood vessels and interfering with the tumor's blood supply."--PBS website
Antiangiogenesis a potential therapeutic strategy by Anthony J Girardi( Book )
2 editions published in 1991 in English and held by 74 WorldCat member libraries worldwide
The Harvey lectures : delivered under the auspices of the Harvey Society of New York 1996-1997 by Harvey Society of New York( Book )
1 edition published in 1998 in English and held by 5 WorldCat member libraries worldwide
Organ perfusion and preservation ( Book )
1 edition published in 1968 in English and held by 4 WorldCat member libraries worldwide
Angiogenesis and cancer ( Book )
2 editions published in 1992 in English and held by 3 WorldCat member libraries worldwide
Prevention of the Angiogenic Switch in Human Breast ( )
2 editions published between 2007 and 2008 in English and held by 2 WorldCat member libraries worldwide
Our overall goal is to determine if human breast cancer can be prevented from becoming angiogenic when it is still at a microscopic size (<~ 1 mm3). To date we have made the following progress: (1) We have cloned three different human breast cancers that undergo the angiogenic switch at predictable times. (2) We have found that the angiogenic switch time is modified by host stroma: two-fold earlier for tumors in the mammary fat pad, compared to tumors implanted in subcutaneous tissue. (3) We have found that the angiogenic switch is preceded by repression of stromal expression of thrombospodin-1. Angiogenic tumor cells continue to secrete a novel thrombospondin-1 repressing factor. This protein has been purified and partially sequenced. (4) For one of the breast cancers, the angiogenic switch can be detected at a microscopic size by a significant increase in bFGF in platelet alpha granules. (5) We have determined that the BRCA1 gene (breast cancer susceptibility gene), appears to regulate a ratio of thromobospondin-1 to VEGF in breast cancer cells. The lower the thrombospondin-1/VEGF ratio, the sooner the tumor cells will spontaneously switch to the angiogenic phenotype and grow large tumors in SCID mice
Angiogenesis Research to Improve Therapies for Vascular Leak Syndromes, Intra-Abdominal Adhesions, and Arterial Injuries ( )
2 editions published between 2006 and 2007 in English and held by 2 WorldCat member libraries worldwide
The three goals of this project are: (i) to discover and develop novel drugs which could prevent or reverse the vascular leak syndrome; (ii) to develop angiogenesis inhibitors which would inhibit post-operative abdominal adhesions; and, (iii) to isolate endothelial progenitor cells from blood, capable of being expanded in vitro and applied to vascular grafts. Progress has been made in each category: we have demonstrated suppression of vascular leak by Caplostatin in response to the pro-angiogenic agent VEGF; we have demonstrated that celebrex has an effect on adhesion prevention, and we have two other angiogenesis inhibitors that we would now like to test; and, we have identified cells from cord blood and adult bone marrow that can substitute for mature smooth muscle cells isolated from a healthy vein
Prevention of the Angioenic Switch in Human Breast Cancer ( )
2 editions published between 2005 and 2006 in English and held by 2 WorldCat member libraries worldwide
The overall goal of this research is to determine if human breast cancer can be prevented from becoming angiogenic when it is still at a microscopic size of less than approximately 1 mm(sub 3). We have made the following progress during the past year: (1) We have developed models in SCID mice of four different non-angiogenic human breast cancers, and have shown that the time to the switch to the angiogenic phenotype is predictable and reproducible for each different breast cancer type. The same is true for the percentage of tumors that become angiogenic. (2) Two angiogenesis-based biomarkers have been developed to detect the angiogenic switch when these tumors are still at a microscopic size of 1 mm(sub 3) or less. The most sensitive and accurate biomarker is the "platelet angiogenic profile," which determines and quantifies the angiogenic regulatory proteins being elaborated by a tumor. A second biomarker is a rise in circulating precursor endothelial cells exiting from the bone marrow and stimulated by a tumor that is undergoing the angiogenic switch. Our translational goal is to treat human breast cancer, both primary and recurrent, with non-toxic angiogenesis inhibitors guided by biomarkers before tumors can be anatomically located
Pediatric surgery what a surgeon needs to know about childhood cancer ( Recording )
1 edition published in 1981 in English and held by 1 WorldCat member library worldwide
The Harvey lectures ( Book )
1 edition published in 1998 in English and held by 1 WorldCat member library worldwide
Angiogenesis Research to Improve Therapies for Vascular Leak Syndromes, Intra-abdominal Adhesions, and Arterial Injuries ( )
1 edition published in 2008 in English and held by 1 WorldCat member library worldwide
The three goals of this project are: (i) to discover and develop novel drugs which could prevent or reverse the vascular leak syndrome; (ii) to develop angiogenesis inhibitors which would inhibit post-operative abdominal adhesions; and, (iii) to isolate endothelial progenitor cells from blood, capable of being expanded in vitro and applied to vascular grafts. Progress has been made in each category: we have demonstrated that the widely used antibiotic, doxycyline, is a potent inhibitor of VEGF-induced vascular leak, and that a combination of Lodamin and doxycycline have additive effects and inhibit vascular leakage by greater than 80%; we have established that sunitinib likely does prevent intra-abdominal postoperative adhesions in rabbits; and, we have isolated and characterized mesenchymal progenitor cells (MPCs) from human adult bone marrow and from human cord blood; showed expansion potential suitable for tissue engineering and tissue regeneration applications
Francis Daniels Moore : August 17, 1913-November 24, 2001 by M. Judah Folkman( Book )
1 edition published in 2006 in English and held by 1 WorldCat member library worldwide
Doxycycline Inhibits Vascular Leakage and Prevents the Development of Pulmonary Edema ( )
1 edition published in 2008 in English and held by 1 WorldCat member library worldwide
The Vascular Leak Syndrome induced by blast injuries, burns, asphyxiation, and other injuries lead to progressive pulmonary edema, as well as tissue and limb swelling that contribute to morbidity and mortality of soldiers on the battlefield. The main goal of our research is the development and validation of novel therapies to prevent and reverse vascular leak syndromes. Our findings indicate that doxycycline, a commonly used antibiotic, inhibits vascular leak in a spectrum of pathologies
Thalidomide a second chance? ( Visual )
1 edition published in 2004 in English and held by 1 WorldCat member library worldwide
Documentary looking at the history of the drug thalidomide. The first part of the programme examines the discovery of the drug in Germany in 1954 and subsequent popularity as 'Distaval', prescribed as a tranquiliser for anxiety and morning sickness during pregnancy. It turned out to be one of the biggest disasters in medical history after women in the early stages of pregnancy, even if they took just one dose of the drug, gave birth to children with shortened arms and legs. The drug was banned in 1962 but three years later was used to successfully treat the skin lesions of ENL (erythema nodosum leprosum), a side effect of leprosy. It has also been used to treat painful ulcers in Behcet's Disease sufferers. It was found that multiple myeloma, a form of blood cancer, was brought under control through the use of thalidomide, but there are side effects that can lead to neuropathy. An alternative drug, Revimin, has been developed which appears to hold no risk of birth defects or side effects. Thalidomide caused a revolution in the way scientists think about treatment of cancer and the programme ends by suggesting that because of this, the drug may be 'making amends' for the horrors it was previously responsible for
New directions in angiogenesis research ( Visual )
1 edition published in 1997 in English and held by 1 WorldCat member library worldwide
Calabresi lecture June 11, 1998, Fitkin Amphitheater by M. Judah Folkman( Visual )
1 edition published in 1998 in English and held by 1 WorldCat member library worldwide
Investigations in pediatric cardiac surgery : with contributions to the repair of ventricular septal defects and to the correction of complete heart block by M. Judah Folkman( Book )
1 edition published in 1957 in English and held by 1 WorldCat member library worldwide
Polymers for the sustained release of proteins and other macromolecules by Robert Langer( Book )
1 edition published in 1976 in English and held by 1 WorldCat member library worldwide
Anti-agiogenic therapy of experimental cancer by M. Judah Folkman( Visual )
1 edition published in 1999 in English and held by 1 WorldCat member library worldwide
At a NIST colloquium held March 5, 1999 at the National Institute of Standards and Technology, Dr. Folkman discusses anti-angiogenic drugs and how they can slow tumor growth by stopping the process of developing new blood vessels and interfering with the tumor's blood supply
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.39 (from 0.00 for Angiogenes ... to 1.00 for Angiogenes ...)
Alternative Names
Folkman, Judah
Folkman, Judah 1933-2008
Folkman, Moses Judah
Languages
English (53)
Chinese (4)
Portuguese (1)
Covers